全文获取类型
收费全文 | 320926篇 |
免费 | 18881篇 |
国内免费 | 477篇 |
专业分类
耳鼻咽喉 | 4544篇 |
儿科学 | 12275篇 |
妇产科学 | 10846篇 |
基础医学 | 47840篇 |
口腔科学 | 7931篇 |
临床医学 | 25530篇 |
内科学 | 60411篇 |
皮肤病学 | 7282篇 |
神经病学 | 22102篇 |
特种医学 | 12538篇 |
外国民族医学 | 43篇 |
外科学 | 50444篇 |
综合类 | 8662篇 |
现状与发展 | 1篇 |
一般理论 | 170篇 |
预防医学 | 21143篇 |
眼科学 | 8245篇 |
药学 | 22941篇 |
中国医学 | 925篇 |
肿瘤学 | 16411篇 |
出版年
2021年 | 2913篇 |
2019年 | 2702篇 |
2018年 | 4288篇 |
2017年 | 3095篇 |
2016年 | 3716篇 |
2015年 | 4054篇 |
2014年 | 5467篇 |
2013年 | 8258篇 |
2012年 | 10542篇 |
2011年 | 11030篇 |
2010年 | 6987篇 |
2009年 | 6238篇 |
2008年 | 9877篇 |
2007年 | 10798篇 |
2006年 | 10448篇 |
2005年 | 9997篇 |
2004年 | 9598篇 |
2003年 | 9034篇 |
2002年 | 8540篇 |
2001年 | 14024篇 |
2000年 | 14322篇 |
1999年 | 12003篇 |
1998年 | 3264篇 |
1997年 | 2965篇 |
1996年 | 2774篇 |
1995年 | 2678篇 |
1992年 | 8659篇 |
1991年 | 8831篇 |
1990年 | 8591篇 |
1989年 | 8427篇 |
1988年 | 7617篇 |
1987年 | 7338篇 |
1986年 | 6982篇 |
1985年 | 6782篇 |
1984年 | 4968篇 |
1983年 | 4290篇 |
1982年 | 2576篇 |
1979年 | 4653篇 |
1978年 | 3378篇 |
1977年 | 2872篇 |
1976年 | 2630篇 |
1975年 | 2985篇 |
1974年 | 3497篇 |
1973年 | 3529篇 |
1972年 | 3249篇 |
1971年 | 3057篇 |
1970年 | 2934篇 |
1969年 | 2678篇 |
1968年 | 2639篇 |
1967年 | 2471篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Apoorva Challa Neeraj Mahajan Seema Sood Arti Kapil Bimal Kumar Das Vishnubhatla Sreenivas Somesh Gupta 《Indian journal of medical microbiology》2022,40(3):433-435
Treatment guidelines for management of uncomplicated gonorrhoeae have been recently modified owing to alarming upsurge in azithromycin resistance. This study investigated the prevalence and genetic determinants of gonococcal azithromycin resistance in India. Four (5.7%) of 70 gonococcal isolates were resistant to azithromycin. Of 16 isolates investigated for molecular mechanisms of resistance, 13 (81.3%) and 6 (37.5%) isolates exhibited mutations in coding and promoter regions of mtrR gene, respectively. However, ermA, ermB and ermC genes or mutations in rrl gene were absent in all isolates. Azithromycin resistance is low in India posing no immediate threat to use of dual-therapy for syndromic management. 相似文献
3.
4.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
5.
6.
7.
8.
9.